Related Experiment Video
Updated: May 20, 2026
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice
Emilie Saussereau1, Laurent Debarbieux
1Institut Pasteur, Molecular Biology of the Gene in Extremophiles Unit, Department of Microbiology, Paris, France.
Abstract:
The regular increase of drug-resistant pathogens has been a major force in the renewed interest in the use of bacteriophages as therapeutics. In addition to experience acquired in eastern Europe where bacteriophages have been used to treat bacterial infections in humans, in Western countries only experimental models have been developed until recently. The Gram-negative bacterium Pseudomonas aeruginosa is an opportunistic pathogen causing particularly severe infections in cystic fibrosis patients. Several experimental models in mice have yielded encouraging results for the use of bacteriophages to treat or prevent septicemia, skin and lungs infections caused by P. aeruginosa. Now, a phase II clinical trial conducted in the United Kingdom provides evidence for the efficacy of bacteriophage treatments in chronic otitis due to antibiotic-resistant P. aeruginosa strains. Together with experimental models, these results provide an incentive to develop more research and clinical studies to fully appreciate the benefits of the use of bacteriophages in medicine.
Insights
Bacteriophages show promise for treating infections caused by drug-resistant bacteria like Pseudomonas aeruginosa. A UK clinical trial demonstrated their efficacy in chronic ear infections, supporting further research into phage therapy.
Area of Science:
- Microbiology
- Infectious Diseases
- Therapeutic Development
Background:
- Rising antibiotic resistance necessitates novel therapeutic strategies.
- Bacteriophages (phages) are viruses that infect bacteria and are being explored as an alternative to antibiotics.
- Pseudomonas aeruginosa is a significant opportunistic pathogen, particularly in cystic fibrosis patients.
Purpose of the Study:
- To evaluate the efficacy of bacteriophage therapy against antibiotic-resistant Pseudomonas aeruginosa.
- To provide clinical evidence supporting the use of phages as a treatment for bacterial infections.
Main Methods:
- Review of experimental models in mice for P. aeruginosa infections.
- Analysis of a Phase II clinical trial in the UK for chronic otitis caused by P. aeruginosa.
- Assessment of bacteriophage efficacy in treating bacterial infections.
Main Results:
- Experimental models in mice showed encouraging results for treating P. aeruginosa infections.
- A UK Phase II clinical trial demonstrated bacteriophage efficacy in treating chronic otitis media caused by antibiotic-resistant P. aeruginosa.
- Phage therapy shows potential for managing infections where antibiotics are failing.
Conclusions:
- Bacteriophage therapy is a promising alternative for treating infections caused by drug-resistant pathogens.
- Clinical evidence supports the use of bacteriophages, particularly against P. aeruginosa.
- Further research and clinical studies are warranted to fully establish the benefits of phage therapy in medicine.
